0001603345 2026-04-01 2026-09-30 0001603345 agtx:SoftwareSubscriptionMember 2026-09-30 0001603345 agtx:SoftwareSubscriptionMember 2026-03-31 0001603345 agtx:ServicesMember 2026-03-31 0001603345 agtx:SoftwareSubscriptionMember 2026-04-01 2026-09-30 0001603345 agtx:ServicesMember 2026-09-30 0001603345 agtx:ServicesMember 2026-04-01 2026-09-30 0001603345 agtx:GraysPeakMember 2023-01-01 2023-01-15 0001603345 agtx:GraysPeakMember 2023-06-15 0001603345 agtx:GraysPeakMember 2023-01-15 0001603345 agtx:PresidentandBoardmemberMember 2026-03-31 0001603345 agtx:SBSManagementMember 2025-04-01 2025-09-30 0001603345 agtx:SBSManagementMember 2026-04-01 2026-09-30 0001603345 agtx:SBSManagementMember 2026-07-01 2026-09-30 0001603345 agtx:SBSManagementMember 2025-07-01 2025-09-30 0001603345 agtx:GraysPeakMember 2026-03-31 0001603345 agtx:GraysPeakMember 2026-09-30 0001603345 agtx:SBSManagementMember 2026-03-31 0001603345 agtx:SBSManagementMember 2026-09-30 0001603345 agtx:PresidentandBoardmemberMember 2026-09-30 0001603345 agtx:GSLHealthcareMember 2026-09-30 0001603345 us-gaap:RetainedEarningsMember 2026-09-30 0001603345 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-09-30 0001603345 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001603345 agtx:CommonStocktobeIssuedMember 2026-09-30 0001603345 us-gaap:CommonStockMember 2026-09-30 0001603345 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001603345 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-07-01 2026-09-30 0001603345 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001603345 agtx:CommonStocktobeIssuedMember 2026-07-01 2026-09-30 0001603345 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001603345 2026-06-30 0001603345 us-gaap:RetainedEarningsMember 2026-06-30 0001603345 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-06-30 0001603345 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001603345 agtx:CommonStocktobeIssuedMember 2026-06-30 0001603345 us-gaap:CommonStockMember 2026-06-30 0001603345 2026-04-01 2026-06-30 0001603345 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001603345 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-04-01 2026-06-30 0001603345 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001603345 agtx:CommonStocktobeIssuedMember 2026-04-01 2026-06-30 0001603345 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001603345 us-gaap:RetainedEarningsMember 2026-03-31 0001603345 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001603345 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001603345 agtx:CommonStocktobeIssuedMember 2026-03-31 0001603345 us-gaap:CommonStockMember 2026-03-31 0001603345 2025-09-30 0001603345 us-gaap:RetainedEarningsMember 2025-09-30 0001603345 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0001603345 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001603345 agtx:CommonStocktobeIssuedMember 2025-09-30 0001603345 us-gaap:CommonStockMember 2025-09-30 0001603345 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001603345 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0001603345 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001603345 agtx:CommonStocktobeIssuedMember 2025-07-01 2025-09-30 0001603345 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001603345 2025-06-30 0001603345 us-gaap:RetainedEarningsMember 2025-06-30 0001603345 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001603345 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001603345 agtx:CommonStocktobeIssuedMember 2025-06-30 0001603345 us-gaap:CommonStockMember 2025-06-30 0001603345 2025-04-01 2025-06-30 0001603345 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001603345 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001603345 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001603345 agtx:CommonStocktobeIssuedMember 2025-04-01 2025-06-30 0001603345 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001603345 2025-03-31 0001603345 us-gaap:RetainedEarningsMember 2025-03-31 0001603345 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001603345 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001603345 agtx:CommonStocktobeIssuedMember 2025-03-31 0001603345 us-gaap:CommonStockMember 2025-03-31 0001603345 2025-04-01 2025-09-30 0001603345 2025-07-01 2025-09-30 0001603345 2026-07-01 2026-09-30 0001603345 2026-03-31 0001603345 2026-09-30 0001603345 2026-11-06 iso4217:USD shares iso4217:USD shares pure 0001603345 false --03-31 Q2 2027

0.001

50000000

40066951

357102

false false false false

250000

107102

10-Q true 2026-09-30 false 000-55383 AGENTIX CORP. NV 46-2876282 32932 Pacific Coast Highway #14-254 Dana Point CA 92629 321 299-2014 Yes Yes Non-accelerated Filer true true true false 40066951

1312

771

1312

771

1312

771

714408

715870

2519108 2383073 386700 353450

188121

143889

3808337

3596282

3808337

3596282

0.001

50000000

40066951

40067

357102

53535 53535

3288296

26940

29755

-7215863

-7007164

-3807025

-3595511

1312

771

47193

81233

109277

163858

4191

25079

20826

125079

16785

33570

34502

68169

123097

163673

323439

-68169

-123097

-163673

-323439

302

3149

302

18289

23158

24159

45328

45385

20604

-22856

-21010

-45026

-6492

-91025

-144107

-208699

-329931

-91025

-144107

-208699

-329931

-2207

-2165

-2815

16142

-93232

-146272

-211514

-313789

-0.00

-0.01

40066951

40067

53535

3288296

35381

-6521528

-3104249

18307

-185824

40066951

40067

53535

3288296

53688

-6707352

-3271766

-2165

-144107

40066951

40067

53535

3288296

51523

-6851459

-3418038

40066951

40067

53535

3288296

29755

-7007164

-3595511

-608

-117674

40066951

40067

53535

3288296

29147

-7124838

-3713793

-2207

-91025

40066951

40067

53535

3288296

26940

-7215863

-3807025

-208699

-329931

0 20604

-95797

178805

139371

-29894

-115367

33250

100350

33250

100350

-2815

16141

541

1124

771

4477

1312

5601

Note 1 - Organization and Basis of Presentation Description of the Company FairWind Energy, Inc. (the “Company”) was incorporated on April 18, 2013 under the laws of the State of Nevada. Effective June 17, 2019, the Company changed its name to Agentix Corp. In March 2022, the Company changed its fiscal year end from August to March. The Company is a clinical-stage biotechnology company developing therapeutic agents for the treatment of metabolic disease like Type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Going Concern The Company’s unaudited consolidated financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. As reflected in the unaudited consolidated financial statements, the Company had an accumulated deficit of $7,215,863 as of September 30, 2026, a net loss of $208,699 and net cash used in operating activities of $29,894 for the six months ended September 30, 2026, and negative working capital of $3,807,025 as of September 30, 2026. Cash on hand as of September 30, 2026 was $1,312. The Company is attempting to commence operations and generate sufficient revenue; however, the Company’s cash position is not sufficient to support its daily operations, and it will need further funding. The ability of the Company to continue as a going concern is dependent upon its ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds. The unaudited consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Principles of Consolidation The unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, GSL Healthcare, Inc., AB Merger LLC, Agentix Australia Pty Ltd, and Applied Biopharma, all of which are 100% owned by the Company. Intercompany transactions and balances have been eliminated in consolidation. Except for Agentix Australia Pty Ltd, the Company’s subsidiaries had no material operations or activity during the periods presented.

-7215863

-208699

-29894

-3807025

1312

Note 2 - Significant and Critical Accounting Policies and Practices Basis of Presentation The accompanying unaudited consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) applicable to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements reflect all adjustments (consisting of normal recurring accruals) that, in the opinion of management, are necessary for a fair statement of the results for the interim periods presented. Unaudited interim results are not necessarily indicative of results for the full fiscal year. These financial statements should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026. Prepayment Prepayments were $0 as of September 30, 2026 and March 31, 2026. Fair Value of Financial Instruments The Company follows paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in generally accepted accounting principles (GAAP) and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:8%;vertical-align:top;">Level 1</td><td style="vertical-align:top;">Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Level 2</td><td style="vertical-align:top;">Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Level 3</td><td style="vertical-align:top;">Pricing inputs that are generally unobservable inputs and not corroborated by market data.</td></tr></tbody></table> Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair values because of the short maturity of these instruments. Research and Development The Company follows paragraph 730-10-25-1 of the FASB Accounting Standards Codification (formerly Statement of Financial Accounting Standards No. 2 “Accounting for Research and Development Costs”) and paragraph 730-20-25-11 of the FASB Accounting Standards Codification (formerly Statement of Financial Accounting Standards No. 68 “Research and Development Arrangements”) for research and development costs. Research and development costs are charged to expense as incurred. Research and development costs consist primarily of remuneration for material and testing costs for research and development. Related Parties The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20 the related parties include a. affiliates (“Affiliate” means, with respect to any specified Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act) of the Company; b. entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Deferred Tax Assets and Income Tax Provision The Company accounts for income taxes under Section 740-10-30 of the FASB Accounting Standards Codification. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the period that includes the enactment date. The Company adopted section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. Earnings per Share Earnings per share (“EPS”) are the amount of earnings attributable to each share of common stock. For convenience, the term is used to refer to either earnings or loss per share. EPS is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Pursuant to ASC Paragraphs 260-10-45-10 through 260-10-45-16, basic EPS shall be computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Income available to common stockholders shall be computed by deducting both the dividends declared in the period on preferred stock (whether or not paid) and the dividends accumulated for the period on cumulative preferred stock (whether or not earned) from income from continuing operations (if that amount appears in the income statement) and also from net income. The computation of diluted EPS is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued during the period to reflect the potential dilution that could occur from common shares issuable through contingent shares issuance arrangement, stock options or warrants. Pursuant to ASC Paragraphs 260-10-45-21 through 260-10-45-23 Diluted EPS shall be based on the most advantageous conversion rate or exercise price from the standpoint of the security holder. The dilutive effect of outstanding call options and warrants (and their equivalents) issued by the reporting entity shall be reflected in diluted EPS by application of the treasury stock method unless the provisions of paragraphs 260-10-45-35 through 45-36 and 260-10-55-8 through 55-11 require that another method be applied. Equivalents of options and warrants include non-vested stock granted to employees, stock purchase contracts, and partially paid stock subscriptions (see paragraph 260–10–55–23). Anti-dilutive contracts, such as purchased put options and purchased call options, shall be excluded from diluted EPS. Under the treasury stock method: a. Exercise of options and warrants shall be assumed at the beginning of the period (or at time of issuance, if later) and common shares shall be assumed to be issued. b. The proceeds from exercise shall be assumed to be used to purchase common stock at the average market price during the period. (See paragraphs 260-10-45-29 and 260-10-55-4 through 55-5.) c. The incremental shares (the difference between the number of shares assumed issued and the number of shares assumed purchased) shall be included in the denominator of the diluted EPS computation. Basic and diluted loss per share was $0.00 for the three months ended September 30, 2026 and 2025 and $0.01 for the six months ended September 30, 2026 and 2025. Weighted-average common shares outstanding were 40,066,951 in each period. Stock-Based Payments Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718, “Compensation — Stock Compensation” (“ASC 718”), which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). ASC 718 also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. For non-employees, the Company follows ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. Under the ASU No. 2018-07, most of the guidance on stock payments to nonemployees is aligned with the requirements for share-based payments granted to employees. As such, most of the guidance in ASC 718 associated with employee share-based payments, including most requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. No stock options or warrants were issued or outstanding as of September 30, 2026 and March 31, 2026. Recent Accounting Pronouncements There have been no recent accounting pronouncements or changes in accounting pronouncements during the six months ended September 30, 2026, as compared to the recent accounting pronouncements described in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026, that are of significance or potential significance to the Company. Commitment and Contingencies The Company accounts for contingencies in accordance with ASC 450-20, Loss Contingencies. Certain conditions may exist as of the date the financial statements are issued that may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities based on available information, and such assessment inherently involves the exercise of judgment. In assessing loss contingencies related to pending legal proceedings or unasserted claims that may result in legal proceedings, the Company evaluates the perceived merits of the matter, the likelihood of an unfavorable outcome, and the amount of relief sought or expected to be sought. If the assessment indicates that it is probable that a loss has been incurred and the amount of the liability can be reasonably estimated, the Company accrues the estimated liability in the financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but the amount cannot be reasonably estimated, the Company discloses the nature of the contingency and an estimate of the possible loss or range of loss, if such estimate can be made and is material. Loss contingencies considered remote are generally not disclosed unless they involve guarantees. The Company has received correspondence from a vendor alleging that approximately $44,991 remains outstanding in connection with prior services allegedly provided to Agentix Australia Pty Ltd. The vendor has indicated that it has commenced debt recovery action and may pursue formal legal proceedings if the amount is not resolved. Management disputes certain aspects of the vendor’s claim, including whether the amounts are valid and payable; the accrued amount as of September 30, 2026 was $44,991. As of September 30, 2026, other than the matter described above, the Company is not aware of any material pending or threatened claims, commitments, or contingencies that would require additional accrual or disclosure in the consolidated financial statements. Segment Reporting The Chief Operating Decision Maker (“CODM”) for the Company is the Chief Executive Officer (the “CEO”). The Company’s CEO reviews operating results on an aggregate basis and manages the Company’s operations as a whole for the purpose of evaluating financial performance and allocating resources. This decision-making process reflects the way in which financial information is regularly reviewed and used by the CODM to evaluate performance, set operational targets, forecast future financial results, and allocate resources. Accordingly, the Company has determined that it has a single reportable and operating segment. The Company’s CODM assesses financial performance and allocates resources based on operating results which are also reported on the accompanying consolidated statements of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM utilizes consolidated operating results by comparing actual results against budgeted amounts. As part of this process, consolidated net loss is a critical performance measure used to evaluate the Company’s operating performance and guide strategic decisions and resource allocations, including additional investments in research and development.

The accompanying unaudited consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) applicable to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements reflect all adjustments (consisting of normal recurring accruals) that, in the opinion of management, are necessary for a fair statement of the results for the interim periods presented. Unaudited interim results are not necessarily indicative of results for the full fiscal year. These financial statements should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026.

Prepayments were $0 as of September 30, 2026 and March 31, 2026.

The Company follows paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in generally accepted accounting principles (GAAP) and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:8%;vertical-align:top;">Level 1</td><td style="vertical-align:top;">Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Level 2</td><td style="vertical-align:top;">Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Level 3</td><td style="vertical-align:top;">Pricing inputs that are generally unobservable inputs and not corroborated by market data.</td></tr></tbody></table> Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair values because of the short maturity of these instruments.

The Company follows paragraph 730-10-25-1 of the FASB Accounting Standards Codification (formerly Statement of Financial Accounting Standards No. 2 “Accounting for Research and Development Costs”) and paragraph 730-20-25-11 of the FASB Accounting Standards Codification (formerly Statement of Financial Accounting Standards No. 68 “Research and Development Arrangements”) for research and development costs. Research and development costs are charged to expense as incurred. Research and development costs consist primarily of remuneration for material and testing costs for research and development.

The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20 the related parties include a. affiliates (“Affiliate” means, with respect to any specified Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act) of the Company; b. entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

The Company accounts for income taxes under Section 740-10-30 of the FASB Accounting Standards Codification. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the period that includes the enactment date. The Company adopted section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.

Earnings per share (“EPS”) are the amount of earnings attributable to each share of common stock. For convenience, the term is used to refer to either earnings or loss per share. EPS is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Pursuant to ASC Paragraphs 260-10-45-10 through 260-10-45-16, basic EPS shall be computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Income available to common stockholders shall be computed by deducting both the dividends declared in the period on preferred stock (whether or not paid) and the dividends accumulated for the period on cumulative preferred stock (whether or not earned) from income from continuing operations (if that amount appears in the income statement) and also from net income. The computation of diluted EPS is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued during the period to reflect the potential dilution that could occur from common shares issuable through contingent shares issuance arrangement, stock options or warrants. Pursuant to ASC Paragraphs 260-10-45-21 through 260-10-45-23 Diluted EPS shall be based on the most advantageous conversion rate or exercise price from the standpoint of the security holder. The dilutive effect of outstanding call options and warrants (and their equivalents) issued by the reporting entity shall be reflected in diluted EPS by application of the treasury stock method unless the provisions of paragraphs 260-10-45-35 through 45-36 and 260-10-55-8 through 55-11 require that another method be applied. Equivalents of options and warrants include non-vested stock granted to employees, stock purchase contracts, and partially paid stock subscriptions (see paragraph 260–10–55–23). Anti-dilutive contracts, such as purchased put options and purchased call options, shall be excluded from diluted EPS. Under the treasury stock method: a. Exercise of options and warrants shall be assumed at the beginning of the period (or at time of issuance, if later) and common shares shall be assumed to be issued. b. The proceeds from exercise shall be assumed to be used to purchase common stock at the average market price during the period. (See paragraphs 260-10-45-29 and 260-10-55-4 through 55-5.) c. The incremental shares (the difference between the number of shares assumed issued and the number of shares assumed purchased) shall be included in the denominator of the diluted EPS computation. Basic and diluted loss per share was $0.00 for the three months ended September 30, 2026 and 2025 and $0.01 for the six months ended September 30, 2026 and 2025. Weighted-average common shares outstanding were 40,066,951 in each period.

-0.00

-0.01

40066951

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718, “Compensation — Stock Compensation” (“ASC 718”), which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). ASC 718 also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. For non-employees, the Company follows ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. Under the ASU No. 2018-07, most of the guidance on stock payments to nonemployees is aligned with the requirements for share-based payments granted to employees. As such, most of the guidance in ASC 718 associated with employee share-based payments, including most requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. No stock options or warrants were issued or outstanding as of September 30, 2026 and March 31, 2026.

There have been no recent accounting pronouncements or changes in accounting pronouncements during the six months ended September 30, 2026, as compared to the recent accounting pronouncements described in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026, that are of significance or potential significance to the Company.

The Company accounts for contingencies in accordance with ASC 450-20, Loss Contingencies. Certain conditions may exist as of the date the financial statements are issued that may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities based on available information, and such assessment inherently involves the exercise of judgment. In assessing loss contingencies related to pending legal proceedings or unasserted claims that may result in legal proceedings, the Company evaluates the perceived merits of the matter, the likelihood of an unfavorable outcome, and the amount of relief sought or expected to be sought. If the assessment indicates that it is probable that a loss has been incurred and the amount of the liability can be reasonably estimated, the Company accrues the estimated liability in the financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but the amount cannot be reasonably estimated, the Company discloses the nature of the contingency and an estimate of the possible loss or range of loss, if such estimate can be made and is material. Loss contingencies considered remote are generally not disclosed unless they involve guarantees. The Company has received correspondence from a vendor alleging that approximately $44,991 remains outstanding in connection with prior services allegedly provided to Agentix Australia Pty Ltd. The vendor has indicated that it has commenced debt recovery action and may pursue formal legal proceedings if the amount is not resolved. Management disputes certain aspects of the vendor’s claim, including whether the amounts are valid and payable; the accrued amount as of September 30, 2026 was $44,991. As of September 30, 2026, other than the matter described above, the Company is not aware of any material pending or threatened claims, commitments, or contingencies that would require additional accrual or disclosure in the consolidated financial statements.

44991

The Chief Operating Decision Maker (“CODM”) for the Company is the Chief Executive Officer (the “CEO”). The Company’s CEO reviews operating results on an aggregate basis and manages the Company’s operations as a whole for the purpose of evaluating financial performance and allocating resources. This decision-making process reflects the way in which financial information is regularly reviewed and used by the CODM to evaluate performance, set operational targets, forecast future financial results, and allocate resources. Accordingly, the Company has determined that it has a single reportable and operating segment. The Company’s CODM assesses financial performance and allocates resources based on operating results which are also reported on the accompanying consolidated statements of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM utilizes consolidated operating results by comparing actual results against budgeted amounts. As part of this process, consolidated net loss is a critical performance measure used to evaluate the Company’s operating performance and guide strategic decisions and resource allocations, including additional investments in research and development.

Note 3 - Related Parties SBS Management LLC During the three and six months ended September 30, 2026 and 2025, SBS Management LLC, a company controlled by Mr. Scott Stevens, a shareholder of the Company, provided management consulting and other services and paid certain expenses on behalf of the Company. These expenses totaled $62,443 and $110,284 for the three months ended September 30, 2026 and 2025, respectively, and $134,211 and $206,387 for the six months ended September 30, 2026 and 2025, respectively. As of September 30, 2026 and March 31, 2026, $1,619,189 and $1,484,978, respectively, were included in accounts payable - related parties on the accompanying consolidated balance sheets. These advances are unsecured, non-interest bearing, and have no formal terms of repayment. Gray’s Peak Capital Gray’s Peak Capital (“Gray’s Peak”), a company founded by a shareholder of the Company, has provided advances to cover operating expenses. These advances are unsecured, non-interest bearing, and have no formal terms of repayment. As of September 30, 2026 and March 31, 2026, amounts due to Gray’s Peak were $529,073 and $527,248, respectively, and were included in accounts payable - related parties on the accompanying consolidated balance sheets. Gray’s Peak Capital – Note Payable On January 15, 2023 and June 15, 2023, the Company entered into two separate Mezzanine Secured Notes (the “Notes”) in principal amounts of up to $200,000 and $500,000, respectively, with Gray’s Peak Private Credit LLC. For 30 days after the date of each Note, the Note bears interest at 7.5%. After the 30th day, the Note bears interest at 2% per month until paid in full. The Notes originally matured on the fourth and sixth month anniversaries of the respective loan dates. The Company may prepay any portion of a Note without premium or penalty. The January 15, 2023 borrowings were repaid in September 2023. The June 15, 2023 Note had been extended to December 31, 2026. The Notes are secured by a pledge by the Company of favor of Gray’s Peak of all of the assets and property of the Company, including without limitation all R&D tax credits, goods, tangible property, machinery, owned equipment, furniture, fixtures, vehicles, parts, accounts, deposit accounts, letter-of-credit rights, chattel paper, contract rights, documents, instruments, investment property, choses in action, general intangibles, goodwill and intellectual property, of any kind or nature, wherever located, in which Company has an interest now or in the future, and which are now existing or hereafter created or acquired, together with any and all additions, replacements, accessions and substitutions thereto or therefore, and any proceeds thereof excluding equipment leased by the Company (collectively called the “Collateral”). Gray’s Peak interest is senior to the unsecured debt or lenders of the Company and the Company’s equity holders. Upon the occurrence of any Event of Default, as defined in the agreement, the principal sum, all accrued and unpaid interest owing thereon and all costs and expenses payable pursuant to this Note, shall, at the sole option of Gray’s Peak and with submission of written notice, become immediately due and payable. As of September 30, 2026 and March 31, 2026, the principal balance outstanding was $386,700 and $353,450, respectively. The Notes were included in note payable - related party on the accompanying consolidated balance sheets. Accrued interest of $187,567 and $142,238 was included in accrued expenses as of September 30, 2026 and March 31, 2026, respectively. Management As of September 30, 2026 and March 31, 2026, $370,846 and $325,847, respectively, was included in accounts payable - related parties on the accompanying consolidated balance sheets.

62443

110284

134211

206387

1619189 1484978 529073 527248 200000 500000 For 30 days after the date of each Note, the Note bears interest at 7.5%. After the 30th day, the Note bears interest at 2% per month until paid in full 386700 353450

187567

142238

370846 325847

Note 4 - Equity As of September 30, 2026 and March 31, 2026, the Company had authorized 50,000,000 shares of common stock with a par value of $0.001 per share and had 40,066,951 shares issued and outstanding at each date. Shares to be Issued The Company had previously granted 250,000 shares of common stock for services previously provided. As of September 30, 2026 and March 31, 2026, 250,000 of these shares had not been issued and were included in common stock to be issued in the consolidated balance sheets. The Company had previously granted 307,102 shares of common stock in exchange for a one-year software subscription. As of September 30, 2026 and March 31, 2026, 107,102 shares had not been issued and were included in common stock to be issued in the consolidated balance sheets.

50000000

0.001

40066951

250000

307102

107102

Note 5 - Subsequent Events In accordance with ASC 855, the Company has analyzed its operations subsequent to September 30, 2026 through the date these financial statements were issued and has determined that it does not have any other material subsequent events to disclose in these financial statements.